MedWatch

Experiences from Covid-19 will create success for Demant's virtual product launch

It's unfortunate for hearing aid company Demant that the launch of the firm's new flagship manufacturer coincides with the greatest crisis in the history of the industry. But experiences based on the last nine months in Covid-19 alertness cause CEO Søren Nielsen to trust in a successful launch.

Photo: Niels Hougaard/ERH

Since March, when the Covid-19 crisis started, hearing firm Demant has undergone a significant transitional process, where almost all work procedures in the C25 company have been subjected to a 'new normal' with virtual work processes becoming standard rather than physical meetings and face-to-face interactions.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs